Clinical Trial Search

Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)

Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment.(Motor Scores) — 0; 3; 0; 0 Participants

Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05

Primary: Percentage of Participants With Healing by Day 8 — 194 Participants

Primary: Zicam Was Compared to Placebo as a Treatment of Recurrent HSL From the Date and Time of the Initiation of Therapy Until the Date and Time of Resolution of the Lesion or…

Primary: Number of Participants With Bacterial Vaginosis Recurrence — 8 Participants

Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716

Primary: Mean Change From Baseline in Blood Flow — 2558.65; 3470.13; 809.88; 960.86 Perfusion Units — p=0.3061

Primary: Percentage of Participants With Healing by Day 8 — 66.4; 69.5 Percentage of Participants — p=0.5086

Primary: The Quantity of HIV-1 RNA in Plasma While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir. — 4.08; 3.68 log10 copies/mL — p=<0.001

Primary: Serious Adverse Device Effects — 0 Percentage SADE's

Primary: HSV Shedding Rate in Those Receiving Oral TDF, Vaginal TFV, or Double Placebo — 22.9; 13.8; 21.3; 19.5 percentage of swabs positive (%) — p=0.086

Primary: Duration (Days) of Herpes Labialis Outbreak Until Healed — 10.6; 8.25 days

Primary: Lesion Healing — 107.47; 110.08; 112.41 hours

Primary: Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2 — 35; 35 Subjects

Primary: Subjects With at Least One Form of Contact With Study Staff With no Herpes Labialis Outbreaks Within 119 Days of Sensitization — 62.96; 20 percentage of particpants

Primary: Survival With no or Mild Neuropsychological Impairment at 12 Months After Initiation of Study Medication as Measured by the Mattis Dementia Rating Scale (MDRS) — 28; 34…

Primary: Herpes Simplex Virus Type 2 Recurrence — 0; 0 Recurrence

Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…

Primary: Time to Healing of Genital Lesions — 5.1; 6.0 Days

Primary: Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation — -0.53; 0.03 log10 copies/mL

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment (Motor Scores). — 10; 5; 0; 1 participants

Primary: Sensitivity of Detection of HSV DNA by GeneXpert PCR From Specimens Obtained From the Genital Tract of Non-pregnant Women in STI Clinics, as Compared With HSV Culture…

Primary: Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Acyclovir as…

Primary: PANSS Positive and Negative Syndrome Scale for Schizophrenia — 70.08; 83.92; 72.25; 77 Scores on the scale

Primary: Number of Subjects With Serious Adverse Events (SAEs) — 71; 42; 37 Participants

Primary: Number of Participants With Solicited Local and Systemic ARs — 74; 75; 75; 74 Participants

Primary: Percent Change in Overall Viral Shedding Rate From Baseline (Week -7 to 0) to Post-treatment Period (Weeks 6 to 13) — 13.53 percentage change

Primary: Mean Level of HIV-1 RNA in Plasma of Participants While on Acyclovir or Valacyclovir. — 3.56; 2.94 log10 copies/mL